RedHill Biopharma ( (RDHL) ) has issued an update.
RedHill Biopharma presented a business update at the Sachs’ European Life Sciences CEO Forum, highlighting significant corporate activities and advancements. Key developments include a $60 million out-licensing deal with Hyloris for RHB-102, the initiation of a Bayer-funded Phase 2 study of opaganib in prostate cancer, and commercial progress with Talicia, which has surpassed 100,000 prescriptions and expanded its market reach. These strategic moves are expected to enhance RedHill’s market position and financial performance, offering potential benefits to stakeholders.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of drugs for gastrointestinal diseases, infectious diseases, and oncology, primarily in the U.S. The company promotes Talicia® for the treatment of Helicobacter pylori infection and has several late-stage clinical development programs, including opaganib, RHB-107, RHB-102, RHB-104, and RHB-204, targeting various indications such as cancer, inflammatory diseases, and pandemic preparedness.
YTD Price Performance: -39.84%
Average Trading Volume: 56,858
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.91M
For a thorough assessment of RDHL stock, go to TipRanks’ Stock Analysis page.